Cell therapy method for the treatment of tumours

摘要

Treating a subject with cancer comprising combining the CD +>8 cells, which are stimulated with antigen-presenting cell line (nnAPC), with adherent blood monocytes and inoculating the subject with CD8 +> suspension, is new. Treating a subject with cancer comprises: (a) preparing a nnAPC line that is capable of presenting up to about fifteen different peptide molecules associated with cancer simultaneously; (b) harvesting CD8+ cells from the subject or a suitable donor; (c) stimulating the CD8+ cells with nnAPC cell line; (d) adding the CD8 +> to media that contains a cytokine consisting of IL-2, IL-7 or conditioned growth medium (CGM), where the cytokines can be used individually or in combination; (e) mixing unsuspended peripheral blood monocytes, or CD-8 depleted peripheral blood monocytes collected from the subject or a suitable donor with about 1 to 50 Microg/ml of one of the peptides that the nnAPC can simultaneously present; (f) irradiating the peripheral blood monocyte suspension with a sufficient dose of gamma -radiation necessary to sterilize all components in the suspension, except the desired peripheral blood monocytes; (g) isolating adherent peripheral blood monocytes; (h) loading the adherent peripheral blood monocytes with about 1- 50 Microg/ml of each peptide; (i) combining the CD8 +> cells with the adherent peripheral blood monocytes at a ratio of about ten CD8 +> cells to one peripheral blood monocyte; and (j) inoculating the subject with CD8 +> suspension. Independent claims are also included for the following: (1) a nnAPC derived from Drosophila melanogaster cells transfected with nucleic acid that expresses human class I human leukocyte antigen (HLA), binding or co-stimulatory molecules; and (2) a method for manufacturing nnAPC. ACTIVITY : Cytostatic. Test details are described but no results given. MECHANISM OF ACTION : Cell therapy.